Marengo Presents Expanded Clinical Monotherapy Activity of Invikafusp Alfa in Multiple PD-1 Resistant Tumors as a Clinical Plenary Oral at AACR 2025
Invikafusp alfa demonstrates initial durable disease control, tumor regression, and objective responses in both primary and secondary PD-1 resistant tumors including CRC and NSCLCPromising early monotherapy efficacy signal across all


